Literature DB >> 18303106

Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis.

C Hirst1, G Ingram, R Swingler, D A S Compston, T Pickersgill, N P Robertson.   

Abstract

BACKGROUND: In patients with multiple sclerosis (MS), the natural history of the disease is of considerable importance to predict and understand long-term outcome and inform choices made by patients and clinicians. This information should ideally be derived from data that reflects the entire disease course.
METHODS: In this study, morbidity data from a prevalent cohort established in 1985 have been re-examined after an interval of 20 years to assess factors that may be important in determining outcome.
RESULTS: Of 379 patients who fulfilled criteria for definite or probable MS in the original population-based cohort, 221 (58.3%) had died, 149 (39.3%) were alive and 9 (2.4%) were untraceable. Mean Expanded Disability Status Scale (EDSS) score in 1985 was 5.15 (SD 2.7, range 0-9.5) and 8.01 (SD 2.6, range 0-10) in those alive in 2005. Mean worsening of EDSS scores in surviving patients was +3.02 EDSS points, but 14.0% had worsened by <1 EDSS point over 20 years. 61.4% of patients with EDSS 3.5-5.5 and 82.2% of those with an EDSS of <or=3 in 1985 had an EDSS of >or=6 after 20 years. Lower baseline EDSS scores (p<0.0001), higher pyramidal functional system score (p = 0.02) and a greater number of functional systems involved (p = 0.001) were significantly more likely to be associated with greater worsening of disability. Of those with benign disease in 1985, only 19% remained benign after 20 years of follow-up; however, 12.6% of patients had minimal disability after at least 20 years after their disease onset and 14% of patients failed to worsen by >or=1 EDSS point.
CONCLUSIONS: This study emphasises the importance of long-term epidemiological studies and the development of clinically relevant measures that effectively predict outcome and can guide decisions on therapeutic management.

Entities:  

Mesh:

Year:  2008        PMID: 18303106     DOI: 10.1136/jnnp.2007.133785

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America.

Authors:  Adriana Carrá; Miguel Ángel Macías-Islas; Alberto Alan Gabbai; Jorge Correale; Carlos Bolaña; Eduardo Duriez Sotelo; Juan García Bonitto; Fernando Vergara-Edwards; Darwin Vizcarra-Escobar
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

Review 2.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

3.  Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.

Authors:  Arianna Sartori; Mohammad Abdoli; Mark S Freedman
Journal:  J Neurol       Date:  2017-04-17       Impact factor: 4.849

Review 4.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

5.  Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.

Authors:  Kristin M Galetta; Jennifer Graves; Lauren S Talman; Deacon J Lile; Elliot M Frohman; Peter A Calabresi; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2012-06       Impact factor: 3.042

6.  Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.

Authors:  D J Rigotti; A Gass; L Achtnichts; M Inglese; J S Babb; Y Naegelin; J Hirsch; M Amann; L Kappos; O Gonen
Journal:  Mult Scler       Date:  2011-09-15       Impact factor: 6.312

7.  Perspectives on Physical Activity Among People with Multiple Sclerosis Who Are Wheelchair Users: Informing the Design of Future Interventions.

Authors:  Yvonne C Learmonth; Ian M Rice; Teresa Ostler; Laura A Rice; Robert W Motl
Journal:  Int J MS Care       Date:  2015 May-Jun

Review 8.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

Review 9.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

10.  Systemic complement profiling in multiple sclerosis as a biomarker of disease state.

Authors:  G Ingram; S Hakobyan; C L Hirst; C L Harris; S Loveless; J P Mitchell; T P Pickersgill; N P Robertson; B P Morgan
Journal:  Mult Scler       Date:  2012-02-21       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.